Literature DB >> 21700440

Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis.

Willemien P E de Kleijn1, Jolanda De Vries, Petal A H M Wijnen, Marjolein Drent.   

Abstract

OBJECTIVE: The usefulness of any questionnaire in clinical management and research trials depends on its ability to indicate a likelihood of treatment success during follow-up. The Minimal Clinically Important Difference (MCID) reflects a clinically relevant change score. The aim of this study was to estimate the MCID for the Fatigue Assessment Scale (FAS) in patients with sarcoidosis.
METHODS: Outpatients (n = 321) of the ild care team of the Department of Respiratory Medicine of the Maastricht University Medical Centre, The Netherlands, participated in this prospective follow-up study. Anchor-based and distribution-based methods were used to estimate the MCID. Based on the anchor Physical Quality of Life, a Receiver Operating Characteristic (ROC) was obtained. The distribution-based methods consisted of the Effect Size and Standard Error Measurement (SEM).
RESULTS: The anchor-based MCID found with ROC was 3.5. The distribution-based methods showed that the corresponding change scores in the FAS for a small effect was 4.2. The SEM criterion was 3.6 points change in the FAS.
CONCLUSIONS: Based on the anchor-based and distribution-based methods, the MCID is a 4-point difference on the FAS. This MCID can be used in the follow-up of fatigue (FAS) in clinical trials and in the management of individual sarcoidosis cases.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21700440     DOI: 10.1016/j.rmed.2011.05.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

Review 1.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

2.  Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change.

Authors:  Jos Hendrikx; Jaap Fransen; Wietske Kievit; Piet L C M van Riel
Journal:  Qual Life Res       Date:  2014-09-25       Impact factor: 4.147

Review 3.  Diagnosis of Sarcoidosis.

Authors:  Thomas E Wessendorf; Francesco Bonella; Ulrich Costabel
Journal:  Clin Rev Allergy Immunol       Date:  2015-08       Impact factor: 8.667

Review 4.  Optimal management of fatigue in patients with systemic lupus erythematosus: a systematic review.

Authors:  Hon K Yuen; Melissa A Cunningham
Journal:  Ther Clin Risk Manag       Date:  2014-10-01       Impact factor: 2.423

5.  [Guideline S1: Long COVID: Diagnostics and treatment strategies].

Authors:  Susanne Rabady; Johann Altenberger; Markus Brose; Doris-Maria Denk-Linnert; Elisabeth Fertl; Florian Götzinger; Maria de la Cruz Gomez Pellin; Benedikt Hofbaur; Kathryn Hoffmann; Renate Hoffmann-Dorninger; Rembert Koczulla; Oliver Lammel; Bernd Lamprecht; Judith Löffler-Ragg; Christian A Müller; Stefanie Poggenburg; Hans Rittmannsberger; Paul Sator; Volker Strenger; Karin Vonbank; Johannes Wancata; Thomas Weber; Jörg Weber; Günter Weiss; Maria Wendler; Ralf-Harun Zwick
Journal:  Wien Klin Wochenschr       Date:  2021-12-01       Impact factor: 1.704

6.  Benefits of Physical Training in Sarcoidosis.

Authors:  Bert Strookappe; Jeff Swigris; Jolanda De Vries; Marjon Elfferich; Ton Knevel; Marjolein Drent
Journal:  Lung       Date:  2015-08-19       Impact factor: 2.584

7.  Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.

Authors:  Elyse E Lower; Atul Malhotra; Victoria Surdulescu; Robert P Baughman
Journal:  J Pain Symptom Manage       Date:  2012-08-20       Impact factor: 3.612

8.  Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study.

Authors:  Rik G J Marcellis; Antoine F Lenssen; Stephan Kleynen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2013-04-05       Impact factor: 2.584

9.  Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.

Authors:  Robert P Baughman; Oksana A Shlobin; Rohit Gupta; Peter J Engel; Jeffrey I Stewart; Elyse E Lower; Franck F Rahaghi; Joyce Zeigler; Steven D Nathan
Journal:  Chest       Date:  2021-08-04       Impact factor: 9.410

Review 10.  Managing fatigue in sarcoidosis - A systematic review of the evidence.

Authors:  Chris Atkins; Andrew M Wilson
Journal:  Chron Respir Dis       Date:  2016-08-09       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.